PuSH - Publikationsserver des Helmholtz Zentrums München

Zimmermann, G.S. ; von Wulffen, W. ; Huppmann, P. ; Meis, T. ; Ihle, F. ; Geiseler, J.* ; Leuchte, H.H.* ; Tufman, A. ; Behr, J. ; Neurohr, C.

Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.

Respirology 19, 700-706 (2014)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Background and objective Interstitial lung diseases (ILD) are often associated with pulmonary hypertension (PH). This study aimed to evaluate the therapeutic benefit of phosphodiesterase-5 (PDE-5) inhibitors in pulmonary hypertension secondary to ILD. Methods Patients with ILD and PH were treated with sildenafil or tadalafil. Right heart catheterization was performed before and after a minimum of 3-month treatment. In addition, lung function, 6-min walk distance (6MWD) and plasma brain natriuretic peptide (BNP) concentration were assessed. Results Ten ILD patients (three female, mean age 64.4 +/- 9.0 years, six with idiopathic pulmonary fibrosis (IPF), four with hypersensitivity pneumonitis, (HP)) with significant precapillary PH (mean pulmonary artery pressure (PAPm)25mmHg, pulmonary vascular resistance (PVR)>280 dyn*s*cm-5; pulmonary artery wedge pressure (PAWPm)15mmHg) were treated with either sildenafil (n=5) or tadalafil (n=5). Pulmonary haemodynamics were severely impaired at baseline (PAPm 42.9 +/- 5.4mmHg; cardiac index (CI) 2.7 +/- 0.6 L/min/m2; PVR 519 +/- 131 dynxsecxcm-5). After mean follow-up of 6.9 +/- 5.8 months an increase in CI (2.9 +/- 0.7 L/min/m2, P=0.04) and a decrease in PVR (403 +/- 190 dynxsecxcm-5, P=0.03) were observed. 6MWD and BNP did not change significantly. Conclusions Our data suggest that treatment with PDE-5 inhibitors improves pulmonary haemodynamic patients with PH secondary to ILD.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Idiopathic Pulmonary Fibrosis ; Interstitial Lung Disease ; Phosphodiesterase 5 Inhibitor ; Pulmonary Fibrosis ; Pulmonary Hypertension; Brain Natriuretic Peptide; Arterial-hypertension; Controlled-trial; Fibrosis; Sildenafil; Statement; Therapy; Guidelines; Expression; Exercise
ISSN (print) / ISBN 1323-7799
e-ISSN 1440-1843
Zeitschrift Respirology
Quellenangaben Band: 19, Heft: 5, Seiten: 700-706 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort Hoboken
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)